Coagulation factor IIa – exosite I (FIIa exosite I)

Coagulation factor IIa, commonly known as thrombin, is a multifunctional serine protease that serves as the final enzyme in the blood coagulation cascade. It possesses two distinct anion-binding regions, exosite I and exosite II, which are located away from the catalytic active site and regulate the enzyme's specificity [1.1.1, 1.3.2]. Exosite I, also referred to as the fibrinogen-binding exosite, is essential for the recognition and binding of key substrates and cofactors, including fibrinogen, protease-activated receptors (PARs) on platelets, and thrombomodulin [1.1.1, 1.3.2]. By mediating these interactions, exosite I facilitates the conversion of fibrinogen to fibrin and the activation of platelets, making it a critical driver of both physiological hemostasis and pathological thrombosis [1.2.1, 1.3.2]. Therapeutic targeting of exosite I, often through bivalent inhibitors like bivalirudin or specific aptamers like HD1, aims to prevent clot formation by blocking substrate access to the enzyme [1.3.1, 1.5.1]. This approach is widely used in the management of conditions such as acute coronary syndrome and heparin-induced thrombocytopenia, though the primary clinical challenge remains the risk of major bleeding [1.4.1, 1.4.4].

Other names

Anion-binding exosite IFibrinogen-binding exositeThrombin exosite I

Direct thrombin inhibition through exosite I binding, which sterically hinders the docking of macromolecular substrates such as fibrinogen and protease-activated receptors (PARs), thereby preventing fibrin formation and platelet activation [1.3.1, 1.3.2].